ESTRO 2025 - Abstract Book

S2403

Interdisciplinary – Other

ESTRO 2025

Figure 1: P-values comparing baseline ± 2-4 days versus 1 week post-SABR. Where additional significance was observed at one month post-SABR, the average is shown.

Conclusion SABR-induced immune responses appear to vary by fractionation scheme. Multifractionated schedules appear to more effectively enhance immune modulation, potentially improving long-term patient outcomes. Further research is needed to link fractionation schemes with clinical outcomes and to optimize immunotherapy integration with SABR for maximum benefit.

Keywords: SABR, lung, cancer

References 1. Chang, Joe Y et al. SABR with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative NSCLC: an open-label, randomised, phase 2 trial. The Lancet, Volume 402, Issue 10405, 871 – 881 2. M.E. Daly et al. A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT vs. SBRT Alone in High Risk, ES-NSCLC, International Journal of Radiation Oncology*Biology*Physics, Volume 114, Issue 3, Supplement, 2022 3. S.K. Jabbour et al. Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab in Patients with Unresected Stage I or II NSCLC, International Journal of Radiation Oncology*Biology*Physics, Volume 114, Issue 3, Supplement, 2022

3863

Digital Poster Chat iPERTO: empowering radiotherapy patients through artificial intelligence Luís Cunha 1,2 , Barbara Barbosa 1,3,4 , Bruno Mendes 1,5 , Susana Gonçalves 1,2,4 , Cristina Santos 3 , André Soares 3 , Pedro Dias 3 , Marisa Matos 6 1 Medical Physics, Radiobiology and Radiation Protection Group, IPO Porto Research Center (CI-IPOP), Porto Comprehensive Cancer Center (Porto.CCC) & Rise@CI-IPOP (Health Research Network), Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal. 2 Medical Physics Department, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal. 3 Radiotherapy Department, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal. 4 Escola Internacional de Doutoramento, Universidad de Vigo, Vigo, Spain. 5 Faculdade de Engenharia, Universidade do Porto, Porto, Portugal. 6 Nursing Radiotherapy Department